Review



primary antibodies directed against chikv e2  (Kaneka Corp)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    Kaneka Corp primary antibodies directed against chikv e2
    TR-RNAs are efficiently amplified by <t>CHIKV</t> replicase For the in vitro characterization of the taRNA vaccine combinations, HEK 293T cells were transfected with the replicase (nrRNA) or irrelevant RNA (TR-luc) together with the different TR-RNAs or infected with CHIKV (MOI 3). RNA levels were measured by qRT-PCR after 6 h and 16 h with specific primers directed against the <t>E2</t> gene (A) or the capsid gene (B) and normalized to GAPDH. Numbers indicate the fold change in TR-RNA amount after 16 h mediated by the replicase expression. Black circles indicate nr-replicase-RNA-transfected cells and gray rectangles irrelevant RNA. Data are mean ± SEM of three independent experiments.
    Primary Antibodies Directed Against Chikv E2, supplied by Kaneka Corp, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/primary+antibodies+directed+against+chikv+e2/primary+antibodies+directed+against+chikv+e2/pmc09126847-271-23-25
    Average 90 stars, based on 1 article reviews
    primary antibodies directed against chikv e2 - by Bioz Stars, 2026-10
    90/100 stars

    Images

    1) Product Images from "A taRNA vaccine candidate induces a specific immune response that protects mice against Chikungunya virus infections"

    Article Title: A taRNA vaccine candidate induces a specific immune response that protects mice against Chikungunya virus infections

    Journal: Molecular Therapy. Nucleic Acids

    doi: 10.1016/j.omtn.2022.04.036

    TR-RNAs are efficiently amplified by CHIKV replicase For the in vitro characterization of the taRNA vaccine combinations, HEK 293T cells were transfected with the replicase (nrRNA) or irrelevant RNA (TR-luc) together with the different TR-RNAs or infected with CHIKV (MOI 3). RNA levels were measured by qRT-PCR after 6 h and 16 h with specific primers directed against the E2 gene (A) or the capsid gene (B) and normalized to GAPDH. Numbers indicate the fold change in TR-RNA amount after 16 h mediated by the replicase expression. Black circles indicate nr-replicase-RNA-transfected cells and gray rectangles irrelevant RNA. Data are mean ± SEM of three independent experiments.
    Figure Legend Snippet: TR-RNAs are efficiently amplified by CHIKV replicase For the in vitro characterization of the taRNA vaccine combinations, HEK 293T cells were transfected with the replicase (nrRNA) or irrelevant RNA (TR-luc) together with the different TR-RNAs or infected with CHIKV (MOI 3). RNA levels were measured by qRT-PCR after 6 h and 16 h with specific primers directed against the E2 gene (A) or the capsid gene (B) and normalized to GAPDH. Numbers indicate the fold change in TR-RNA amount after 16 h mediated by the replicase expression. Black circles indicate nr-replicase-RNA-transfected cells and gray rectangles irrelevant RNA. Data are mean ± SEM of three independent experiments.

    Techniques Used: Amplification, In Vitro, Transfection, Infection, Quantitative RT-PCR, Expressing

    In vitro antigen expression of the taRNA constructs (A) E2 protein expression on the cell surface was determined 16 h after RNA transfection or CHIKV infection (MOI 3) by flow cytometric analysis. Data are mean ± SEM of three independent experiments. As a control, irrelevant RNA (TR-luc) instead of the replicase RNA (nrRNA) was transfected. The mean fluorescent intensity (MFI) indicates the amount of protein on the cell surface. (B) Expression of the indicated proteins was determined in cellular lysates of cells transfected with nr-replicase-RNA and TR-CS-RNA or CHIKV-infected cells (MOI 3) after 6 h and 24 h. (C) E2 and capsid protein expression after transfection of the nr-replicase-RNA with the TR-RNA combinations of either TR-CS, TR-S alone, or with both TR-S and TR-C was determined in cellular lysates or concentrated supernatants 48 h after transfection. The depicted western blots are representative of three independent experiments.
    Figure Legend Snippet: In vitro antigen expression of the taRNA constructs (A) E2 protein expression on the cell surface was determined 16 h after RNA transfection or CHIKV infection (MOI 3) by flow cytometric analysis. Data are mean ± SEM of three independent experiments. As a control, irrelevant RNA (TR-luc) instead of the replicase RNA (nrRNA) was transfected. The mean fluorescent intensity (MFI) indicates the amount of protein on the cell surface. (B) Expression of the indicated proteins was determined in cellular lysates of cells transfected with nr-replicase-RNA and TR-CS-RNA or CHIKV-infected cells (MOI 3) after 6 h and 24 h. (C) E2 and capsid protein expression after transfection of the nr-replicase-RNA with the TR-RNA combinations of either TR-CS, TR-S alone, or with both TR-S and TR-C was determined in cellular lysates or concentrated supernatants 48 h after transfection. The depicted western blots are representative of three independent experiments.

    Techniques Used: In Vitro, Expressing, Construct, Transfection, Infection, Western Blot

    Related Articles

    Incubation:

    Article Title: A taRNA vaccine candidate induces a specific immune response that protects mice against Chikungunya virus infections
    Article Snippet: After 24 h incubation at 37°C, cells were fixed, permeabilized with 0.5% Triton X-100 in PBS, and stained with primary antibodies directed against CHIKV E2 (Eurogentec, Cologne, Germany; custom made) or dsRNA (Scicons, Budapest, Hungary; no. 10010200).

    Staining:

    Article Title: A taRNA vaccine candidate induces a specific immune response that protects mice against Chikungunya virus infections
    Article Snippet: After 24 h incubation at 37°C, cells were fixed, permeabilized with 0.5% Triton X-100 in PBS, and stained with primary antibodies directed against CHIKV E2 (Eurogentec, Cologne, Germany; custom made) or dsRNA (Scicons, Budapest, Hungary; no. 10010200).

    Amplification:

    Article Title: A taRNA vaccine candidate induces a specific immune response that protects mice against Chikungunya virus infections
    Article Snippet: After 24 h incubation at 37°C, cells were fixed, permeabilized with 0.5% Triton X-100 in PBS, and stained with primary antibodies directed against CHIKV E2 (Eurogentec, Cologne, Germany; custom made) or dsRNA (Scicons, Budapest, Hungary; no. 10010200).

    In Vitro:

    Article Title: A taRNA vaccine candidate induces a specific immune response that protects mice against Chikungunya virus infections
    Article Snippet: After 24 h incubation at 37°C, cells were fixed, permeabilized with 0.5% Triton X-100 in PBS, and stained with primary antibodies directed against CHIKV E2 (Eurogentec, Cologne, Germany; custom made) or dsRNA (Scicons, Budapest, Hungary; no. 10010200).

    Transfection:

    Article Title: A taRNA vaccine candidate induces a specific immune response that protects mice against Chikungunya virus infections
    Article Snippet: After 24 h incubation at 37°C, cells were fixed, permeabilized with 0.5% Triton X-100 in PBS, and stained with primary antibodies directed against CHIKV E2 (Eurogentec, Cologne, Germany; custom made) or dsRNA (Scicons, Budapest, Hungary; no. 10010200).

    Infection:

    Article Title: A taRNA vaccine candidate induces a specific immune response that protects mice against Chikungunya virus infections
    Article Snippet: After 24 h incubation at 37°C, cells were fixed, permeabilized with 0.5% Triton X-100 in PBS, and stained with primary antibodies directed against CHIKV E2 (Eurogentec, Cologne, Germany; custom made) or dsRNA (Scicons, Budapest, Hungary; no. 10010200).

    Quantitative RT-PCR:

    Article Title: A taRNA vaccine candidate induces a specific immune response that protects mice against Chikungunya virus infections
    Article Snippet: After 24 h incubation at 37°C, cells were fixed, permeabilized with 0.5% Triton X-100 in PBS, and stained with primary antibodies directed against CHIKV E2 (Eurogentec, Cologne, Germany; custom made) or dsRNA (Scicons, Budapest, Hungary; no. 10010200).

    Expressing:

    Article Title: A taRNA vaccine candidate induces a specific immune response that protects mice against Chikungunya virus infections
    Article Snippet: After 24 h incubation at 37°C, cells were fixed, permeabilized with 0.5% Triton X-100 in PBS, and stained with primary antibodies directed against CHIKV E2 (Eurogentec, Cologne, Germany; custom made) or dsRNA (Scicons, Budapest, Hungary; no. 10010200).

    Construct:

    Article Title: A taRNA vaccine candidate induces a specific immune response that protects mice against Chikungunya virus infections
    Article Snippet: After 24 h incubation at 37°C, cells were fixed, permeabilized with 0.5% Triton X-100 in PBS, and stained with primary antibodies directed against CHIKV E2 (Eurogentec, Cologne, Germany; custom made) or dsRNA (Scicons, Budapest, Hungary; no. 10010200).

    Western Blot:

    Article Title: A taRNA vaccine candidate induces a specific immune response that protects mice against Chikungunya virus infections
    Article Snippet: After 24 h incubation at 37°C, cells were fixed, permeabilized with 0.5% Triton X-100 in PBS, and stained with primary antibodies directed against CHIKV E2 (Eurogentec, Cologne, Germany; custom made) or dsRNA (Scicons, Budapest, Hungary; no. 10010200).



    Similar Products

    primary antibodies directed against chikv e2  (Kaneka Corp)
    90
    Kaneka Corp primary antibodies directed against chikv e2
    TR-RNAs are efficiently amplified by <t>CHIKV</t> replicase For the in vitro characterization of the taRNA vaccine combinations, HEK 293T cells were transfected with the replicase (nrRNA) or irrelevant RNA (TR-luc) together with the different TR-RNAs or infected with CHIKV (MOI 3). RNA levels were measured by qRT-PCR after 6 h and 16 h with specific primers directed against the <t>E2</t> gene (A) or the capsid gene (B) and normalized to GAPDH. Numbers indicate the fold change in TR-RNA amount after 16 h mediated by the replicase expression. Black circles indicate nr-replicase-RNA-transfected cells and gray rectangles irrelevant RNA. Data are mean ± SEM of three independent experiments.
    Primary Antibodies Directed Against Chikv E2, supplied by Kaneka Corp, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/primary+antibodies+directed+against+chikv+e2/primary+antibodies+directed+against+chikv+e2/pmc09126847-271-23-25
    Average 90 stars, based on 1 article reviews
    primary antibodies directed against chikv e2 - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    TR-RNAs are efficiently amplified by CHIKV replicase For the in vitro characterization of the taRNA vaccine combinations, HEK 293T cells were transfected with the replicase (nrRNA) or irrelevant RNA (TR-luc) together with the different TR-RNAs or infected with CHIKV (MOI 3). RNA levels were measured by qRT-PCR after 6 h and 16 h with specific primers directed against the E2 gene (A) or the capsid gene (B) and normalized to GAPDH. Numbers indicate the fold change in TR-RNA amount after 16 h mediated by the replicase expression. Black circles indicate nr-replicase-RNA-transfected cells and gray rectangles irrelevant RNA. Data are mean ± SEM of three independent experiments.

    Journal: Molecular Therapy. Nucleic Acids

    Article Title: A taRNA vaccine candidate induces a specific immune response that protects mice against Chikungunya virus infections

    doi: 10.1016/j.omtn.2022.04.036

    Figure Lengend Snippet: TR-RNAs are efficiently amplified by CHIKV replicase For the in vitro characterization of the taRNA vaccine combinations, HEK 293T cells were transfected with the replicase (nrRNA) or irrelevant RNA (TR-luc) together with the different TR-RNAs or infected with CHIKV (MOI 3). RNA levels were measured by qRT-PCR after 6 h and 16 h with specific primers directed against the E2 gene (A) or the capsid gene (B) and normalized to GAPDH. Numbers indicate the fold change in TR-RNA amount after 16 h mediated by the replicase expression. Black circles indicate nr-replicase-RNA-transfected cells and gray rectangles irrelevant RNA. Data are mean ± SEM of three independent experiments.

    Article Snippet: After 24 h incubation at 37°C, cells were fixed, permeabilized with 0.5% Triton X-100 in PBS, and stained with primary antibodies directed against CHIKV E2 (Eurogentec, Cologne, Germany; custom made) or dsRNA (Scicons, Budapest, Hungary; no. 10010200).

    Techniques: Amplification, In Vitro, Transfection, Infection, Quantitative RT-PCR, Expressing

    In vitro antigen expression of the taRNA constructs (A) E2 protein expression on the cell surface was determined 16 h after RNA transfection or CHIKV infection (MOI 3) by flow cytometric analysis. Data are mean ± SEM of three independent experiments. As a control, irrelevant RNA (TR-luc) instead of the replicase RNA (nrRNA) was transfected. The mean fluorescent intensity (MFI) indicates the amount of protein on the cell surface. (B) Expression of the indicated proteins was determined in cellular lysates of cells transfected with nr-replicase-RNA and TR-CS-RNA or CHIKV-infected cells (MOI 3) after 6 h and 24 h. (C) E2 and capsid protein expression after transfection of the nr-replicase-RNA with the TR-RNA combinations of either TR-CS, TR-S alone, or with both TR-S and TR-C was determined in cellular lysates or concentrated supernatants 48 h after transfection. The depicted western blots are representative of three independent experiments.

    Journal: Molecular Therapy. Nucleic Acids

    Article Title: A taRNA vaccine candidate induces a specific immune response that protects mice against Chikungunya virus infections

    doi: 10.1016/j.omtn.2022.04.036

    Figure Lengend Snippet: In vitro antigen expression of the taRNA constructs (A) E2 protein expression on the cell surface was determined 16 h after RNA transfection or CHIKV infection (MOI 3) by flow cytometric analysis. Data are mean ± SEM of three independent experiments. As a control, irrelevant RNA (TR-luc) instead of the replicase RNA (nrRNA) was transfected. The mean fluorescent intensity (MFI) indicates the amount of protein on the cell surface. (B) Expression of the indicated proteins was determined in cellular lysates of cells transfected with nr-replicase-RNA and TR-CS-RNA or CHIKV-infected cells (MOI 3) after 6 h and 24 h. (C) E2 and capsid protein expression after transfection of the nr-replicase-RNA with the TR-RNA combinations of either TR-CS, TR-S alone, or with both TR-S and TR-C was determined in cellular lysates or concentrated supernatants 48 h after transfection. The depicted western blots are representative of three independent experiments.

    Article Snippet: After 24 h incubation at 37°C, cells were fixed, permeabilized with 0.5% Triton X-100 in PBS, and stained with primary antibodies directed against CHIKV E2 (Eurogentec, Cologne, Germany; custom made) or dsRNA (Scicons, Budapest, Hungary; no. 10010200).

    Techniques: In Vitro, Expressing, Construct, Transfection, Infection, Western Blot